Article | July 1, 2020

The Time Is Now For Transformation In Clinical Data Collection

By Jim Streeter, global vice president life sciences product strategy, Oracle

Digital-Network-iStock-1023248288

When the COVID-19 pandemic began, many clinical trial teams were forced to quickly find remote methods for collecting data and conducting visits so they could keep patients safe and enrolled in trials that were already underway. This swift transition to virtual clinical trials demonstrated that these approaches are not only possible but can bring real benefits to research studies. It also showed that many of the necessary technologies are mature enough to support these approaches in a practical way.

Importantly, the pandemic also forced pharmaceutical companies, which are understandably careful about making changes that might affect drug approval or increase cost, to look beyond the risks and embrace these new technologies. Regulatory agencies are also now more accepting of changes to how clinical trials have always been done. Together, this creates a climate that is ideal for examining the best way forward for virtual clinical trials and new types of data collection.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: